PER® Miami Breast Cancer Conference | Conference

Local Management in Stage IV Breast Cancer Requires More Refinement

March 5th 2021

Although there is evidence to suggest that surgery with or without radiation therapy can be utilized in some patients with stage IV breast cancer who have experienced locoregional progression or symptoms to some success with regard to locoregional disease control, most patients will not achieve a survival benefit.

Adjuvant CDK4/6 Inhibition Shows Potential in Early HR+/HER2- Breast Cancer, But More Data Are Needed

March 5th 2021

CDK4/6 inhibitors plus aromatase inhibitors have shown benefit as frontline treatment for patients with hormone receptor–positive, HER2-negative advanced breast cancer, but more data are needed to determine their role as adjuvant therapy before they are adopted into standard practice for patients with early-stage disease.

Dr. Brufsky on the Role of Neoadjuvant Chemotherapy in TNBC

March 5th 2021

Adam M. Brufsky, MD, PhD, discusses the role of neoadjuvant chemotherapy in triple-negative breast cancer.

Dr. Borgen on Eliminating Opioid Use in Breast Cancer

March 5th 2021

Patrick I. Borgen, MD, discusses eliminating the use of opioids in patients with breast cancer.

Burnout in Doctors and Mitigation Strategies

March 10th 2020

What may have worked before to mitigate burnout may no longer work now because we change, and so do our work environments.

Navigating Treatment Options for Patients With Early-Stage Breast Cancer

March 10th 2020

Genetic advances have helped elucidate the heterogenous nature of breast cancer, however optimal strategies for patients with early-stage disease still need to be ironed out.

Survivorship Starts at Diagnosis in Breast Cancer

March 10th 2020

The inclusion of patients from the time of diagnosis and encompassing family, friends, and caregivers is central to moving survivorship care forward, especially for breast cancer survivorship, which has high survival rates for early disease and the emergence of novel treatments for advanced cancers.

Navigating the Changing Landscape in HER2-Positive Breast Cancer

March 9th 2020

The paradigm for treating patients with HER2-positive breast cancer is changing throughout the spectrum of the disease as a result of recent clinical trial findings regarding novel and established treatment regimens, according to Sara A. Hurvitz, MD

Dr. O'Shaughnessy on the Utility of Capivasertib in Targeting Akt in Breast Cancer

March 9th 2020

Joyce A. O'Shaughnessy, MD, discusses the utility of targeting capivasertib in targeting Akt mutations in breast cancer.

Dr. Tripathy on Personalized Therapy Options in Metastatic Breast Cancer

March 8th 2020

Debu Tripathy, MD, discusses personalized therapy options in metastatic breast cancer.

Gottlieb Addresses Coronavirus, Innovation in Keynote Address

March 8th 2020

The novel coronavirus spreading across the world represents a distinct challenge for all physicians, especially oncologists who commonly treat patients who have compromised immune systems.

Exercise Programs Improve Outcomes for Patients With Breast Cancer

March 8th 2020

Special attention to reducing the risk of cardiovascular disease should be a priority for long-term care of patients with breast cancer.

Dr. Borgen on the De-Escalation of Surgery in Breast Cancer

March 8th 2020

Patrick I. Borgen, MD, discusses the trend toward surgical de-escalation in patients with breast cancer.

Dr. Soto Perez de Celis on Nuances of Treating Older Patients With Breast Cancer

March 8th 2020

Enrique Soto Pérez de Celis, MD, MSc, discusses nuances of treating older patients with breast cancer.

Novel Antibody-Drug Conjugates Show Encouraging Activity in TNBC

March 7th 2020

Novel antibody-drug conjugates have demonstrated high response rates in patients with heavily pretreated metastatic breast cancer, and ongoing studies targeting actionable cell-surface markers may further expand their clinical utility, according to Aditya Bardia, MD, MPH.

Rugo Spotlights Potential With Tucatinib, Other Novel Agents in HER2+ Breast Cancer

March 7th 2020

Hope S. Rugo, MD, discusses the pending approval of tucatinib in metastatic HER2-positive breast cancer and other potentially practice-changing agents in the pipeline.

All Stakeholders Are Responsible for Genetic Testing

March 7th 2020

Physicians should “get out there and test early and often,” to align with a potential new paradigm for genetic testing that allows anyone on the treatment team to identify and test individuals, with the specialist ultimately providing risk management, according to Kevin S. Hughes, MD, FACS.

Immunotherapy Comes of Age in Breast Cancer

March 7th 2020

Breast cancer has historically been an immunologically cold disease, but recent and emerging data are carving out a space for several immunotherapies in the treatment paradigm.

Dr. Hughes on Genetic Testing in Breast Cancer

March 7th 2020

Kevin Hughes, MD, discusses the role of genetic testing in breast cancer.

Gene Profiling Essential Tool for Treatment Tailoring

March 7th 2020

Gene profiling assays can accurately and reproducibly assist decision making for patients with hormone receptor-positive breast cancer, with the ultimate goal of improving outcomes or avoiding toxicity.